‘Smartening’ anticancer therapeutic nanosystems using biomolecules

Núñez-Lozano, Rebeca; Pimentel, Belén; Cueva-Méndez, Guillermo de la

doi:10.1016/j.copbio.2015.07.005

Cited by 16 publications

(15 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to facilitating cell recognition, the targeting conjugates often promote cellular uptake [234]. Upon binding to their targeted receptors, the NTs are generally shuttled into the cell via endocytosis – the exact endocytic pathway is dependent on factors such as the tumor microenvironment and physicochemical properties of the NT [208].…”

Section: Designing a Nanodrug For Treating Brain Tumorsmentioning

confidence: 99%

“…Upon binding to their targeted receptors, the NTs are generally shuttled into the cell via endocytosis – the exact endocytic pathway is dependent on factors such as the tumor microenvironment and physicochemical properties of the NT [208]. Yet, receptor-mediated interactions do not always promote internalization [234]. To overcome these non-permitting interactions, other entry mechanisms could be exploited.…”

Section: Designing a Nanodrug For Treating Brain Tumorsmentioning

confidence: 99%

See 1 more Smart Citation

Covalent nano delivery systems for selective imaging and treatment of brain tumors

Ljubimova

Sun

Mashouf

et al. 2017

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Nanomedicine is a rapidly evolving form of therapy that holds a great promise in superior drug delivery efficiency and therapeutic efficacy than conventional cancer treatment. In this review, we attempt to cover the benefits and the limitations of current nanomedicines with special attention to covalent nanoconjugates for imaging and drug delivery in brain. The improvement in brain tumor treatment remains dismal despite decades of efforts in drug development and patient care. One of the major obstacles in brain cancer treatment is the poor drug delivery efficiency owing to the unique blood-brain-barrier (BBB) in the CNS. Although various anti-cancer agents are available to treat tumors outside of the CNS, the majority fails to cross the BBB. In this regard, nanomedicines have increasingly drawn attention due to their multi-functionality and versatility. Nano-drugs can penetrate BBB and other biological barriers, and selectively accumulate in tumor cells, while concurrently decreasing systemic toxicity.

show abstract

Section: Designing a Nanodrug For Treating Brain Tumorsmentioning

confidence: 99%

Section: Designing a Nanodrug For Treating Brain Tumorsmentioning

confidence: 99%

Covalent nano delivery systems for selective imaging and treatment of brain tumors

Ljubimova

Sun

Mashouf

et al. 2017

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

show abstract

“…It has drawn increasing attention from both the academic and industrial sectors for applications not only in materials science and engineering, but also in the biotechnology and medical fields including disease diagnostics, prevention, and treatment. Nanomedicine has the potential to modify the pharmacokinetics (PK) of entrapped drugs and therefore favor drug distribution to the target site with little toxicity to healthy cells . In 1995, the first nanoparticle formulation—Doxil was approved for cancer treatment; since then, various nanocarriers have been developed to overcome the physiological barriers as well as to deliver drug efficiently.…”

Section: Introductionmentioning

confidence: 99%

“…Nanomedicine has the potential to modify the pharmacokinetics (PK) of entrapped drugs and therefore favor drug distribution to the target site with little toxicity to healthy cells. [6] In 1995, the first nanoparticle formulation-Doxil was approved for cancer treatment; since then, various nanocarriers have been developed to overcome the physiological barriers as well as to deliver drug efficiently. However, design parameters of nanocarriers are generally based on empirical reasoning.…”

Section: Introductionmentioning

confidence: 99%

Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment

Peng

Bariwal

Kumar

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

Nanocarriers have the capability to deliver a variety of drugs to disease sites. Different biological barriers prevent the successful delivery of nanoformulations to target sites, thereby limiting effective therapeutic response. Although numerous efforts have been made to design novel nanocarriers by incorporating various functionalities to get better therapies, most strategies have failed to translate drug delivery systems to the clinic. Impediments such as the incapability to hold drugs stably in nanocarriers during circulation, non‐specific distribution, and inadequate delivery of therapeutic agents to target sites due to complex tumor microenvironment remain a challenge. Herein, different organic polymer and lipid‐based nanocarriers and their encouraging therapeutic effectiveness to treat cancer are discussed. Recent development in multifunctional and stimuli sensitive nanocarriers is also highlighted. Finally, the challenges and innovative strategies to overcome various obstacles and limitations for their successful translation into the clinic are discussed.

show abstract

“…acid aptamers [42] and peptides, [43] can be assembled with the DNA nanostructures in site-specific and quantitycontrolled ways. Chemical modifications with tumor targeting effects enable nanostructure vehicles to discriminate malignant cells from healthy ones and reduce side effects.…”

Section: Introductionmentioning

confidence: 99%

Self‐Assembled DNA Nanostructures for Drug Delivery

et al. 2016

View full text Add to dashboard Cite

Due to the uniform nanoscale sizes, well-defined shapes, precise spatial addressability and prominent biocompatibility, self-assembled DNA nanostructures have been intensively studied for their biomedical applications. This review summarizes the recent development of DNA nanotechnology in cancer therapy, and discusses the challenges and potential strategies to advance the methodologies of cancer treatments.

show abstract

‘Smartening’ anticancer therapeutic nanosystems using biomolecules

Cited by 16 publications

References 62 publications

Covalent nano delivery systems for selective imaging and treatment of brain tumors

Covalent nano delivery systems for selective imaging and treatment of brain tumors

Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment

Self‐Assembled DNA Nanostructures for Drug Delivery

Contact Info

Product

Resources

About